<DOC>
	<DOC>NCT00496470</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>&gt;=40 years of age, diagnosed COPD with symptoms &gt;=2 years, prebronchodilatory FEV1 &lt;=50% of PN Current respiratory tract disorder other than COPD, history of asthma or rhinitis, significant or unstable cardiovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease, COPD</keyword>
</DOC>